Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18135496 | 0.83 | SLC6A2 (0.44) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL22912455 | 0.81 | TAAR1 (0.39) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL13153419 | 0.79 | TAAR1 (0.52) | SLC6A2SLC6A4ADRA1ASLC6A3KCNH2 | |
| SCHEMBL13153417 | 0.79 | RIPK1 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1AOC3 | |
| SCHEMBL13153418 | 0.77 | RIPK1 (0.49) | SLC6A2SLC6A3ALDH1A1MEN1KMT2A | |
| SCHEMBL9023235 | 0.77 | KCNH2 (0.40) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL733940 | 0.75 | KMT2A (0.45) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL22651832 | 0.75 | HTR2A (0.57) | ADRA2CSLC6A2HTR2ASLC6A4ADRA1A | |
| SCHEMBL24716193 | 0.75 | TSHR (0.41) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL13463904 | 0.75 | ALDH1A1 (0.39) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874409-A | Green debenzylation method by photocatalytic molecular oxygen oxidation | 大连理工大学 | 2023-10-13 | — | — | CN | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2022-10-18 | — | — | US | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-11185853-B2 | Catalysts for polycarbonate production | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2021-11-30 | — | — | US | disclosed |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2020-11-12 | — | — | US | disclosed |
| US-10662211-B2 | Catalysts and methods for polymer synthesis | Saurdi Aramco Technologies Company (SA) | 2020-05-26 | — | — | US | disclosed |
| US-10479861-B2 | Catalytic carbonylation catalysts and methods | NOVOMER, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10464960-B2 | Salen complexes with dianionic counterions | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2019-11-05 | — | — | US | disclosed |
| US-20130144033-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130144031-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130144032-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-8129561-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2012-03-06 | — | — | US | disclosed |
| US-20110152497-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ADRA2B 639/4885ADRA2C 469/4885SLC6A2 2127/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | ADRA2B 3942/4885ADRA2C 4163/4885SLC6A2 4301/4885 |
| US-10662211-B2 | Catalysts and methods for polymer synthesis | PPOX, COASY, SOD1 | ADRA2B 4872/4885ADRA2C 4799/4885SLC6A2 4530/4885 |
| US-10464960-B2 | Salen complexes with dianionic counterions | NCLN, POLN, NCL | ADRA2B 3542/4885ADRA2C 3404/4885SLC6A2 812/4885 |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | ADORA1, OXGR1, ADORA2A | ADRA2B 153/4885ADRA2C 205/4885SLC6A2 459/4885 |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | TPMT, ADORA2A, PNP | ADRA2B 1543/4885ADRA2C 1342/4885SLC6A2 50/4885 |
| US-20130144032-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | ADRA2B 4872/4885ADRA2C 4799/4885SLC6A2 4530/4885 |
| US-10479861-B2 | Catalytic carbonylation catalysts and methods | CBR3, CBR1, EPHX2 | ADRA2B 4775/4885ADRA2C 4205/4885SLC6A2 4712/4885 |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ADRA2B 639/4885ADRA2C 469/4885SLC6A2 2127/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | ADRA2B 3870/4885ADRA2C 3994/4885SLC6A2 4192/4885 |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | TPMT, ADORA2A, PNP | ADRA2B 1543/4885ADRA2C 1342/4885SLC6A2 50/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | ADRA2B 517/4885ADRA2C 766/4885SLC6A2 652/4885 |
| US-20130144033-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | ADRA2B 4872/4885ADRA2C 4799/4885SLC6A2 4530/4885 |
| US-20120270877-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | ADRA2B 4316/4885ADRA2C 4393/4885SLC6A2 4150/4885 |
| US-20110152497-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | ADRA2B 4872/4885ADRA2C 4799/4885SLC6A2 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.